Competing interests
Thomas’ NHS, P.
MUSCLE WASTING
This work was supported (in part) by the ASPEN Rhoads Research Foundation. D. E. B. reports speaker fees from, Baxter Healthcare; advisory board fees from Baxter Healthcare;. N. H. reports unrestricted grants from Philips and ResMed outside the direct area of work commented on here with the funds held and managed by Guy’s and St Thomas’ NHS Foundation Trust; financial support from Philips for the development of MYOTRACE technology that has a patent filed in Europe (US pending) outside the area of work commented on here; personal fees for lecturing from Philips-Respironics, Philips, ResMed, and Fisher-Paykel both within and outside the area of work commented on here; N. H. is on the Pulmonary Research Advisory Board for Philips outside the area of work commented on here with the funds for this role held by Guy’s and St Thomas’ NHS Foundation Trust. H. E. M. has a patent, “The Use of Inhibitors of the Renin-Angiotensin System,” which relates in part to the prevention of muscle wasting, issued. Z. A. P. reports personal fees from Faraday Pharmaceuticals, Lyric Pharmaceuticals,Bioage, Fresenius Kabi, Nestlé, Orion, and GlaxoSmithKline, outside the submitted work. 
None declared (DW, IJG, AM,PJA, ALG, MRC, TF, SDR).